Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(71.4%)
Phase 4
2(28.6%)
7Total
N/A(5)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05347901Unknown

Clinical Precise Diagnosis and Treatment in the Kawasaki Disease

Role: collaborator

NCT05816642Not ApplicableUnknown

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Role: collaborator

NCT05783115Not ApplicableUnknown

Multicentre Study on Diabetic Foot Treatment

Role: collaborator

NCT05671276Phase 4Unknown

Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion

Role: collaborator

NCT04909528Not ApplicableUnknown

LLTS to Treat Premature Ventricular Contractions

Role: collaborator

NCT05420480Not ApplicableNot Yet Recruiting

Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy

Role: collaborator

NCT03462628Not ApplicableCompleted

Additional Low Voltage Area Ablation in Older Patients With Paroxysmal Atrial Fibrillation

Role: collaborator

NCT02473406Phase 4Completed

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

Role: collaborator

All 8 trials loaded